Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

Blood (2018) 132 (Supplement 1): 459.

https://doi.org/10.1182/blood-2018-99-110569

Published: 2018

Journal Articles

Integration of Multiple Bioassays Using Machine Learning to Identify High-Risk CP-CML Patients Treated with Frontline Imatinib

Chung Hoow Kok, PhD BSc, Sakrapee Paisitkriangkrai, PhD, David T Yeung, PhD BSc, FRACP, FRCPA MBBS, Liu Liu, PhD BSc, Verity A Saunders, Phuong Dang, Agnes S. M. Yong, MD PhD, Deborah L White, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2018-99-117633

Published: 2018

Journal Articles

High Recombination Activating Gene (RAG) Expression and RAG Mediated Recombination Is Associated with Oncogenic Rearrangement Observed with Tyrosine Kinase Inhibitor Resistant CML

Daniel Thomson, PhD BSc, Hezrin Shahrin, PhD, Paul Wang, PhD, Carol Wadham, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Andreas Schreiber, PhD, Susan Branford, PhD

Blood (2018) 132 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2018-99-111212

Published: 2018

Journal Articles

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Blood (2017) 130 (Supplement 1): 2896.

https://doi.org/10.1182/blood.V130.Suppl_1.2896.2896

Published: 2017

Journal Articles

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Blood (2017) 130 (Supplement 1): 2898.

https://doi.org/10.1182/blood.V130.Suppl_1.2898.2898

Published: 2017

Journal Articles

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

Blood (2017) 130 (Supplement 1): 251.

https://doi.org/10.1182/blood.V130.Suppl_1.251.251

Published: 2017

Journal Articles

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Blood (2017) 130 (Supplement 1): 1617.

https://doi.org/10.1182/blood.V130.Suppl_1.1617.1617

Published: 2017

Journal Articles

Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen-Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling

Amy Hughes, PhD, Jade Clarson, Deborah L White, PhD FFSc (RCPA), David Yeung, PhDBSc,FRACP,FRCPA,MBBS, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Agnes S. M. Yong, MDPhD

Blood (2017) 130 (Supplement 1): 1581.

https://doi.org/10.1182/blood.V130.Suppl_1.1581.1581

Published: 2017

Journal Articles

Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

Naranie Shanmuganathan, MBBS, Susan Branford, PhD, David Yeung, PhDBSc,FRACP,FRCPA,MBBS, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Agnes S. M. Yong, MDPhD, David M Ross, MBBS, PhD FRACP, FRCPA, Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1621.

https://doi.org/10.1182/blood.V130.Suppl_1.1621.1621

Published: 2017

Journal Articles

High Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells

Jueqiong WANG, PhD, Chung Hoow Kok, PhD, Tamara M Leclercq, PhD, Verity A Saunders, BSc (Hons), Richard J D'Andrea, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Deborah L White, PhD FFSc (RCPA)

Blood (2015) 126 (23): 2770.

https://doi.org/10.1182/blood.V126.23.2770.2770

Published: 2015

Journal Articles

BCR-ABL Assay Sensitivity of MR4.5 Achieved in >90%, and MR5 in >75% of Samples, through mRNA Selection before qRT-PCR

David T Yeung, BSc, MBBS, FRACP, FRCPA, Wendy Tara Parker, PhD, Stuart Phillis, B Biotech, Jasmina Georgievski, BSc, Hamish S Scott, BSc, PhD FFSc (RCPA), Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Susan Branford, PhDFFSc (RCPA)

Blood (2015) 126 (23): 2777.

https://doi.org/10.1182/blood.V126.23.2777.2777

Published: 2015

Journal Articles

Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Andreas Hochhaus, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Richard A. Larson, MD, Lilia Taningco, MSc, Weiping Deng, Hans D Menssen, MD PhD, Hagop M. Kantarjian, MD

Blood (2015) 126 (23): 2781.

https://doi.org/10.1182/blood.V126.23.2781.2781

Published: 2015

Journal Articles

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Blood (2015) 126 (23): 4025.

https://doi.org/10.1182/blood.V126.23.4025.4025

Published: 2015

Journal Articles

Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)

Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Francisco Cervantes, Nelson Spector, MD PhD, Brian Leber, MD, Susan Branford, PhDFFSc (RCPA), Tara A. Glynos, BS, Sandip Acharya, MSc, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 4029.

https://doi.org/10.1182/blood.V126.23.4029.4029

Published: 2015

Journal Articles

Chronic Myeloid Leukemia Patients with Deep Molecular Responses to Tyrosine Kinase Inhibitors Have Increased Effector Natural Killer and Cytotoxic T Cell Immune Responses to Leukaemia-Associated Antigens and Concomitant Reduced Immune Suppressors

Amy Hughes, B.Sc (hons), PhD, Carine Tang, B.Sc (hons), PhD, Jade Clarson, B.Sc, Ljiljana Vidovic, Animal Sc (hons), Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Agnes S Yong, MD PhD

Blood (2015) 126 (23): 18.

https://doi.org/10.1182/blood.V126.23.18.18

Published: 2015

Journal Articles

High Incidence of Mutated Cancer-Associated Genes at Diagnosis in CML Patients with Early Transformation to Blast Crisis

Susan Branford, PhDFFSc (RCPA), Paul PS Wang, PhD, Wendy Tara Parker, PhD, David Yeung, Justine E Marum, PhD, Doris Stangl, PhD, Zoe Donaldson, Alexandra Yeoman, Nathalie Nataren, Ieuan Walker, Leanne Purins, Bradley Chereda, PhD, Christopher N Hahn, PhD, Hamish S Scott, BSc, PhD FFSc (RCPA), Andreas Schreiber, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 600.

https://doi.org/10.1182/blood.V126.23.600.600

Published: 2015

Journal Articles

A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib

Chung Hoow Kok, PhD, Tamara M Leclercq, PhD, Dale Watkins, PhD, David T Yeung, BSc, MBBS, FRACP, FRCPA, Verity A Saunders, BSc (Hons), Deborah L White, PhD FFSc (RCPA), Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 596.

https://doi.org/10.1182/blood.V126.23.596.596

Published: 2015

Journal Articles

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

Oliver G. Ottmann, MD, Giuliana Alimena, Daniel J. DeAngelo, MD PhD, Yeow-Tee Goh, MBBS, MMed, Michael C. Heinrich, MD, Andreas Hochhaus, MD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Francois-Xavier Mahon, MD PhD Professor, Michael J. Mauro, MD, Hironobu Minami, MD D.MDSci., Marie Huong Nguyen, MD, Delphine Rea, Juan Luis Steegmann, MD, Arkendu Chatterjee, Varsha Iyer, Noelia Martinez, Gary J. Vanasse, MD, Kim Dong-Wook, MD PhD

Blood (2015) 126 (23): 138.

https://doi.org/10.1182/blood.V126.23.138.138

Published: 2015

Journal Articles

High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment

Blood (2015) 126 (23): 1419.

https://doi.org/10.1182/blood.V126.23.1419.1419

Published: 2015

Journal Articles

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Blood (2015) 126 (23): 5142.

https://doi.org/10.1182/blood.V126.23.5142.5142

Published: 2015

NARROW

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

Integration of Multiple Bioassays Using Machine Learning to Identify High-Risk CP-CML Patients Treated with Frontline Imatinib

High Recombination Activating Gene (RAG) Expression and RAG Mediated Recombination Is Associated with Oncogenic Rearrangement Observed with Tyrosine Kinase Inhibitor Resistant CML

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen-Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling

Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

High Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells

BCR-ABL Assay Sensitivity of MR4.5 Achieved in >90%, and MR5 in >75% of Samples, through mRNA Selection before qRT-PCR

Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)

Chronic Myeloid Leukemia Patients with Deep Molecular Responses to Tyrosine Kinase Inhibitors Have Increased Effector Natural Killer and Cytotoxic T Cell Immune Responses to Leukaemia-Associated Antigens and Concomitant Reduced Immune Suppressors

High Incidence of Mutated Cancer-Associated Genes at Diagnosis in CML Patients with Early Transformation to Blast Crisis

A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only